Dashboard
1
Poor Management Efficiency with a low ROCE of 1.82%
- The company has been able to generate a Return on Capital Employed (avg) of 1.82% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -0.70% and Operating profit at -19.02% over the last 5 years
3
The company has declared Negative results for the last 4 consecutive quarters
4
With ROE of 8.56%, it has a attractive valuation with a 1.16 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 5,801 Million (Mid Cap)
14.00
NA
1.11%
-0.41
8.56%
1.16
Revenue and Profits:
Net Sales:
356 Million
(Quarterly Results - Jun 2025)
Net Profit:
289 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.37%
0%
-16.37%
6 Months
0.1%
0%
0.1%
1 Year
13.51%
0%
13.51%
2 Years
3.2%
0%
3.2%
3 Years
21.37%
0%
21.37%
4 Years
44.33%
0%
44.33%
5 Years
13.98%
0%
13.98%
Tianjin Lisheng Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-0.70%
EBIT Growth (5y)
-19.02%
EBIT to Interest (avg)
34.34
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.25
Tax Ratio
14.16%
Dividend Payout Ratio
48.50%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.82%
ROE (avg)
3.32%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
1.16
EV to EBIT
95.14
EV to EBITDA
30.99
EV to Capital Employed
1.27
EV to Sales
2.88
PEG Ratio
0.90
Dividend Yield
1.11%
ROCE (Latest)
1.34%
ROE (Latest)
8.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
355.70
364.20
-2.33%
Operating Profit (PBDIT) excl Other Income
35.70
54.70
-34.73%
Interest
0.90
0.40
125.00%
Exceptional Items
-1.20
1.00
-220.00%
Consolidate Net Profit
288.80
56.60
410.25%
Operating Profit Margin (Excl OI)
44.40%
95.60%
-5.12%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -2.33% vs 18.71% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 410.25% vs 221.59% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,312.80
1,130.20
16.16%
Operating Profit (PBDIT) excl Other Income
147.60
179.90
-17.95%
Interest
3.60
0.90
300.00%
Exceptional Items
16.30
-14.80
210.14%
Consolidate Net Profit
186.00
361.80
-48.59%
Operating Profit Margin (Excl OI)
50.60%
99.70%
-4.91%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 16.16% vs 0.69% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -48.59% vs 286.54% in Dec 2023
About Tianjin Lisheng Pharmaceutical Co., Ltd. 
Tianjin Lisheng Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






